Medtech Trends 2026: Market Dynamics and Strategic Implications

Subheadline: How Pricing Pressures, Outpatient Migration, Supply Chain Realignment, GLP-1 Therapies, and Platform Technologies Are Reshaping the Medical Device Industry

Executive Summary

The medical technology (medtech) landscape is entering a period of accelerated change, driven by structural forces across global pricing, care delivery, supply chains, clinical pathways, and enabling technologies. Clarivate's Medtech Trends to Watch 2026 report identifies five key trends that are redefining competitive dynamics and market opportunities: the expansion of China's volume-based procurement (VBP) program, the continued migration of procedures to outpatient settings, the strategic imperative of supply chain resilience, the ripple effects of GLP-1 receptor agonists on metabolic care pathways, and the shift toward platform-based competition powered by robotics, imaging, navigation, and digital workflows. For medtech companies, understanding these trends is no longer optional; it is essential for portfolio strategy, commercial model adaptation, and long-term growth in an increasingly complex global environment.

Introduction

The medtech industry in 2026 operates at the intersection of scientific innovation, regulatory evolution, and shifting market demands. Companies that once relied on product-centric differentiation now confront a landscape where pricing policies in one region, reimbursement decisions in another, and the rise of digital ecosystems can fundamentally alter competitive advantage. The convergence of these forces demands a more sophisticated, data-driven approach to strategy. This article examines the five medtech trends highlighted in Clarivate's report, drawing on industry intelligence to explore what each trend means for device manufacturers, healthcare providers, patients, and investors. By analyzing the evidence, clinical implications, and future outlook, we aim to provide a balanced perspective on how the medical device sector is evolving and where the next waves of innovation are likely to emerge.

Scientific Background

Medtech encompasses a broad range of products, from surgical instruments and implantable devices to diagnostic platforms and digital health tools. The adoption of these technologies is heavily influenced by clinical evidence, regulatory approval pathways, and reimbursement policies. In recent years, the industry has seen rapid advances in areas such as robotic-assisted surgery, minimally invasive procedures, continuous glucose monitoring, and AI-powered diagnostic software. However, the translation of these innovations into routine clinical practice depends on economic and structural factors that extend beyond technical performance. Clarivate's analysis leverages proprietary market data and expert insights to identify the trends that are most likely to shape the industry over the next 12 to 24 months. The five trends outlined below are not isolated phenomena; they are interconnected and reinforce each other in ways that companies must understand to navigate the evolving medtech landscape effectively.

Research Findings

1. Mainland China's VBP Expansion Is Redefining Global Market Economics

China's volume-based procurement (VBP) program, initially introduced to expand patient access to high-quality medical devices while controlling costs, has evolved into a powerful market-structuring mechanism. The latest national VBP round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. This is not a localized policy; it is influencing expectations around price, volume, and competitive positioning in markets well beyond China. Multinational medtech companies must now consider how VBP-driven price benchmarks affect their global pricing strategies and portfolio decisions. The program is also accelerating domestic innovation, as local companies gain market share and invest in R&D, which could reshape the competitive landscape both within China and internationally.

2. Outpatient and ASC Settings Are Becoming Central to Procedure Strategy

The migration of surgical procedures from hospital inpatient settings to outpatient ambulatory surgical centers (ASCs) continues to be a defining trend. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment System Final Rule reinforces this shift by expanding the ASC Covered Procedure List and phasing out the inpatient-only list. This change opens the door for higher-acuity procedures, such as cardiac ablation, to transition to lower-cost outpatient settings when clinically appropriate. The trend builds on long-running patterns in orthopedics, general surgery, and other specialties, where ASCs have become critical sites of care. For medtech companies, this requires adapting commercial models, value propositions, and even product designs to meet the needs of diverse sites of service. Devices may need to be less invasive, easier to use, and compatible with ASC workflows and reimbursement structures.

3. Global Trade and Supply Chain Pressures Are Reshaping Manufacturing Strategy

Supply chain resilience has emerged as a strategic imperative for medtech manufacturers. Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging long-held assumptions about where and how devices are produced. Companies are diversifying sourcing, reevaluating business strategies, and pursuing more flexible multi-region manufacturing footprints to mitigate risks. Larger manufacturers are leveraging scale, vertical integration, and technology investments to buffer against global volatility, which could further concentrate competitive advantage among major players. The cost structure, supplier concentration, and manufacturing geography are now critical determinants of competitive advantage, alongside product performance and clinical efficacy. Medtech companies that fail to address supply chain fragility may find themselves at a significant disadvantage in an increasingly unpredictable global environment.

4. GLP-1 Therapies Are Shifting Patient Behavior and Reshaping Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and metabolic conditions is having a profound effect on patient behavior and clinical pathways. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded rapidly in popularity, altering referral patterns and influencing demand across adjacent medtech categories. The impact is not uniform across all bariatric procedures; some are experiencing sharper volume pressure than others. Downstream effects are emerging in areas such as diabetes care, sleep apnea, and cardiovascular monitoring. The GLP-1 effect reflects a broader shift in how metabolic disease is managed, moving toward more integrated, multi-modal approaches. For medtech companies, this means reassessing forecasts for related device markets, understanding new patient journeys, and identifying opportunities to support medical therapy rather than solely surgical intervention.

5. Enabling Technologies Are Driving the Shift Toward Platform-Based Competition

Across medtech, enabling technologies such as robotics, imaging, navigation, and digital workflow software are reshaping competitive differentiation. These technologies are no longer adjuncts to procedures; they are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Companies are investing heavily in platform architectures that anchor entire service lines, strengthen customer relationships, and unlock new data-driven value propositions. Emerging open-platform systems are also expanding flexibility and creating new competitive dynamics, allowing multiple devices and software applications to interoperate. This shift is redefining how companies deliver value, engage with healthcare providers, and build long-term strategic advantage. Organizations that succeed in this new environment will likely be those that can offer comprehensive solutions rather than standalone products.

Industry Impact

The implications of these trends are far-reaching for the biotechnology industry, life sciences sector, and broader healthcare system. For medtech manufacturers, VBP expansion in China necessitates a fundamental reassessment of global pricing and market access strategies. Companies may need to decouple their China strategies from their broader global approaches, focusing on premium segments or partnering with domestic firms to navigate the evolving regulatory and reimbursement landscape. The outpatient migration offers significant growth opportunities for companies that can develop products tailored to ASC settings, including simplified devices, training programs, and economic value propositions that demonstrate cost savings for providers and payers.

Supply chain pressures are likely to accelerate regionalization and reshoring of manufacturing capabilities. This could lead to increased investment in biomanufacturing and microelectronics in North America and Europe, as well as greater diversification across Southeast Asia and other regions. The GLP-1 phenomenon will require medtech companies to become more agile in adjusting their portfolios. For example, companies focused on bariatric surgery may need to expand into metabolic monitoring or digital therapeutics, while those in diabetes care may benefit from increased attention to related conditions such as cardiovascular disease.

Platform-based competition is likely to favor companies with strong software and data analytics capabilities, potentially driving partnerships between traditional device makers and technology firms. The merger of medtech with digital health and artificial intelligence will create new value pools, but also demands new competencies in data management, cybersecurity, and clinical validation. Investment in these areas will be critical for long-term competitiveness. Pharmaceutical and biotech companies should also monitor these trends, as they can affect the adoption of drug-device combination products and the development of integrated care solutions.

Clinical & Regulatory Perspective

The clinical and regulatory landscape is a key determinant of how these trends unfold. VBP in China has implications for patient access and the affordability of innovative devices. While lower prices may increase access to basic technologies, there is a risk that reduced profit margins could dampen investment in next-generation devices, potentially limiting patient access to cutting-edge treatments in the long run. Regulatory agencies in China, including the NMPA, continue to evolve their approval pathways, and device manufacturers must stay abreast of changing requirements for clinical evidence, quality management systems, and post-market surveillance.

The expansion of ASC settings under CMS rules reflects a growing body of evidence that many surgical procedures can be performed safely and effectively in outpatient environments. However, this transition requires careful patient selection, robust safety protocols, and adequate infrastructure. Clinical evidence on patient outcomes in ASCs compared to hospitals will be critical in shaping future reimbursement decisions and specialty guidelines. Medtech companies must generate real-world evidence that supports the use of their devices in these settings, including data on complication rates, recovery times, and patient satisfaction.

GLP-1 therapies, while highly effective for weight loss, come with potential side effects and are not suitable for all patients. The clinical community emphasizes that bariatric surgery remains the most effective option for many individuals with severe obesity. Medtech companies need to develop evidence-based approaches that clarify the role of devices in the continuum of metabolic care, for example, by combining device use with pharmacotherapy or using devices to monitor and manage patients on GLP-1s. Regulatory bodies are also issuing guidance on digital health tools and AI algorithms, requiring robust validation and cybersecurity measures.

Supply chain pressures have regulatory dimensions, including the need to ensure quality and traceability across diverse manufacturing sites. Companies may face additional scrutiny from agencies like the FDA and EMA regarding supply chain resilience, as shortages of critical devices have been a concern in recent years. Regulators are increasingly expecting companies to have contingency plans and diversified sourcing strategies.

Finally, platform technologies that integrate multiple devices, imaging systems, and software raise novel regulatory challenges. The FDA has introduced frameworks for software as a medical device (SaMD) and has emphasized the importance of total product life cycle regulation. As platforms become more interconnected, cybersecurity and data privacy protections will be paramount. Companies must design their systems with security in mind and engage with regulators early to ensure compliance.

Future Outlook

Looking ahead to the next 5–15 years, the trends identified in 2026 are likely to evolve and intensify. China's VBP program will probably continue to expand, but multinational companies may adapt by developing innovative products that meet the value-based procurement criteria or by focusing on high-end segments that are less affected. The global regulatory environment will become more harmonized, with mutual recognition agreements and reliance mechanisms reducing duplication in assessments.

The shift to outpatient and ASC care is expected to continue, with advances in surgical techniques and anesthesiology making more complex procedures feasible in ambulatory settings. This will drive demand for miniaturized, easy-to-use devices and single-use instruments. Digital health platforms will enable remote monitoring and patient engagement, supporting earlier discharge and reducing readmissions.

Supply chain resilience will remain a strategic priority, but companies may move beyond simple diversification to build circular, localized supply chains that leverage additive manufacturing and digital twins. The adoption of Industry 4.0 technologies in biomanufacturing will enhance flexibility and responsiveness, allowing for just-in-time production and customization.

GLP-1 therapies are just the beginning of a broader shift toward pharmacological management of chronic diseases. New agents, including dual and triple agonists, may offer even greater efficacy and target obesity as a chronic disease. Medtech companies will need to embrace a more integrated approach to metabolic health, combining drugs, devices, monitoring, and behavioral support. This could lead to the development of closed-loop systems for metabolic management, akin to artificial pancreas systems.

Platform-based competition will intensify as AI becomes more sophisticated. We can expect to see surgical systems with autonomous capabilities, predictive analytics for patient outcomes, and personalized treatment planning. The convergence of medtech with digital health and genomics will enable truly individualized interventions. However, these advances will require significant investment, and companies that cannot keep pace may face obsolescence.

Innovation ecosystems will be characterized by collaboration among device makers, pharma companies, software developers, and research institutions. Public-private partnerships and joint ventures will become commonplace as companies seek to combine expertise and share risks. Investment in medtech start-ups will continue to grow, with a focus on early-stage companies developing breakthrough technologies.

Key Takeaways

• China's VBP expansion is reshaping global pricing and competitive dynamics; medtech companies need a nuanced China strategy.
• Outpatient and ASC migration demands new commercial models, product designs, and value propositions aligned with lower-cost care settings.
• Supply chain resilience is a strategic necessity; companies should diversify sourcing and adopt flexible manufacturing to mitigate geopolitical and economic risks.
• GLP-1 therapies are altering metabolic care pathways, requiring medtech firms to reassess product portfolios and pursue integrated solutions.
• Enabling technologies are driving platform-based competition, where success hinges on offering integrated ecosystems rather than standalone devices.

Conclusion

As the medtech industry navigates 2026, the forces of pricing reform, care delivery innovation, supply chain restructuring, and technological convergence are creating both challenges and opportunities. The trends highlighted in Clarivate's analysis underscore the need for strategic agility, evidence-based decision-making, and a forward-looking perspective. Companies that embrace these dynamics, invest in innovation, and build resilient operating models will be well-positioned to lead in a rapidly evolving global healthcare landscape. For stakeholders across the life sciences value chain, the message is clear: the future of medtech lies not in technology alone, but in the intelligent integration of science, policy, and market insight.